In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

British Journal of Cancer

Volumn 81, Issue 8, 1999, Pages 1318-1327

  Grosios, K ^a   Holwell, S E ^a   McGown, A T ^b   Pettit, G R ^c   Bibby, M C ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Anti vascular; Colon tumour; Combretastatin A 4; Orthotopic

Indexed keywords

BETA TUBULIN; COLLAGEN; COMBRETASTATIN A4; DISODIUM HYDROGEN PHOSPHATE; F ACTIN; PRODRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATTLE; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; UMBILICAL VEIN; XENOGRAFT;

EID: 0032758736     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6692174     Document Type: Article

References (39)

1. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L and Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 27: 482-487
2. Bibby MC, Double JA, Loadman PM and Duke CV (1989a) Reduction of tumour blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 81: 216-220
3. Bibby MC, Phillips RM and Double JA (1989b) Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol 24: 87-94
4. Bibby MC, Double JA, Phillips RM and Quinn PK (1991a) Flavone acetic acid: is vascular shutdown the crucial mechanism of action. Int J Radiat Biol 60: 395-399
5. Bibby MC, Phillips RM, Double JA and Pratesi G (1991b) Anti-tumour activity of flavone acetic acid (NSC 347512) in mice - influence of immune status. Br J Cancer 63: 57-62
6. Bibby MC, Sleigh NR, Loadman PM and Double JA (1993) Potentiation of EO9 antitumour activity by hydralazine. Eur J Cancer 29A: 1033-1035
7. Birchmeier W (1984) Cytoskeleton, structure and function. Trends Biochem Sci 9: 192-195
8. Borenfreund E, Babich H and Martin-Alguacil N (1990) A rapid chemosensitivity assay with human normal and tumour cells in vitro. In vitro Cell Dev Biol 26: 1030-1034
9. Bujaski A, Nowgrodzka Zagorska M, Lenko J and Miodonski AJ (1989) Angiomorphology of human renal cell carcinoma. Virchows Archiv A Pathol Anat 415: 103-113
10. Chabner BA and Collins JA (1990) Cancer Chemotheraphy: Principles and Practice. JB Lippincott: Philadelphia
11. Chaplin DJ, Peters CE, Horsman MR and Trotter MJ (1991) Drug induced perturbations in tumour blood flow: therapeutic potential and possible limitations. Radiother Oncol 20: 93-101
12. Ching LM, Joseph WR and Baguley BC (1992) Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128-130
13. Clearkin PA (1937) The effect of colchicine on normal and neoplastic tissues in mice. J Pathol Bact 44: 469-480
14. Cowen SE, Bibby MC and Double JA (1995) Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol 34: 357-360
15. Dark GG, Hill SA, Prise VE, Tozer GM, Petlit GR and Chaplin DJ (1997) Combretastatin A 4, an agent that displays potent and selective toxicity towards tumour vasculature. Cancer Res 57: 1829-1834
16. Double JA and Cifuentes de Castro L (1978) Chemotherapy of transplantable adenocarcinomas of the colon in mice. II. Development and characterisation of an ascitic cell line. Cancer Treat Rep 62: 85-90
17. Double JA, Ball CR and Cowen PN (1975) Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst 54: 271-275
18. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM (1988) Identification and characterization of the blood vessels of solid tumours that are leaky to circulating macromolecules. Ant J Pathol 133: 95-109
19. Egawa J and Ishioka K (1979) Construction of blood vessels in experimental tumours some considerations on radioresistance In: Treatment of Radioresistant Cancers, Abe M, Sakamoto K and Phillips TL (eds), pp. 213-227. Elsevier/North Holland Biomedical Press: Amsterdam
20. Geran RI, Greenberg NH and MacDonald MM (1972) Protocols for screening chemical agents and natural products against tumours and other biological systems (Third edition). Cancer Chemother Rep 3: 1-103
21. Hill SA, Sampson LE and Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119-123
22. Jatte E, Nachman R, Becker C and Minick C (1973) Culture of human endothelial cells derived from umbilical veins. J Clin Invest 52: 2745-2756
23. Laws AL, Matthew AM, Double JA and Bibby MC (1995) Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71: 1204-1209
24. McGown AT and Fox BW (1989) Structural and biochemical comparison of the anti-mitotic agents cholchicine, combretastatin A-4 and amphethinile. Anti-Cancer Drug Des 3: 249-254
25. Maciag T, Kadish J, Wilkins L, Stemerman MB and Weinstein R (1982) Organizational behaviour of human umbilical vein endothelial cells. J Cell Biol 94: 511-520
26. Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP and Hart IR (1990) Role of tumour necrosis factor in flavone-acetic acid-induced tumour vasculature shutdown. Cancer Res 50: 5537-5542
27. Montesano R, Orci L and Vassalli P (1983) In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97: 1648-1652
28. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS and Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experietia 45: 209-211
29. Pettit GR, Temple CJR, Nnarayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA and Bansal NN (1995) Antineoplastic agent 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10: 299-309
30. Reweastle GW, Atwell GJ, Baguley BC, Calveley SB and Denny WA (1989) Potential antitumour agents. 58. Synthesis and structure activity relationships of substituted xanthenone-4-acetic acids active against the Colon 38 tumour in vivo. J Med Chem 32: 793-799
31. Rowinsky EK, Cazenave LA and Donchower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259
32. Schiff PB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565
33. Schiff PB, Fant J and Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22: 665-667
34. Schor AM, Schor SL and Allen TD (1983) Effects of culture conditions on the proliferation, morphology and migration of bovine aortic endothelial cells. J Cell Science 62: 267-285
35. Smith KA, Hill SA, Begg AC and Denckamp J (1988). Validation of the fluorescent dye Hocchst 33342 as a vascular space marker in tumours. Br J Cancer 57: 247-253
36. UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia (1998) Br J Cancer 77: 1-10
37. Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumours, A review, Cancer Res 49: 6449-6465
38. Warren BA (1979) The vascular morphology of tumours. In: Tumour Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumours. Peterson H (ed.). pp: 1-47. Franklin, USA
39. Woods JA, Hadfield JA, Pettit GR, Fox BW and McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71: 705-711